Allergan ties up Namenda loose ends with $750M settlement
Allergan, which is in process of being swallowed by AbbVie, is clearing out the cobwebs. On Monday, it agreed to pay $750 million to settle class-action litigation surrounding its Alzheimer’s drug Namenda.
In the summer of 2014, New York’s then-attorney general Eric Schneiderman filed an antitrust lawsuit against a unit of Actavis (now Allergan), alleging that the company had taken illegal steps to delay and impair generic competition for Namenda.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.